Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 6/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276753 | 0.89 | SHBG (0.38) | CYP19A1AKR1B10AKR1B1OR51E2SHBG | |
| SCHEMBL17988645 | 0.89 | SHBG (0.38) | CYP19A1AKR1B10AKR1B1OR51E2SHBG | |
| SCHEMBL9314092 | 0.72 | CYP19A1 (0.38) | CYP19A1AKR1B10AKR1B1OR51E2SHBG | |
| SCHEMBL2457859 | 0.71 | — | — | |
| SCHEMBL2455329 | 0.71 | — | — | |
| SCHEMBL2455331 | 0.71 | — | — | |
| SCHEMBL17048771 | 0.71 | — | — | |
| SCHEMBL2248516 | 0.71 | SHBG (0.36) | SHBG | |
| SCHEMBL2495783 | 0.71 | SHBG (0.36) | SHBG | |
| SCHEMBL2246359 | 0.71 | SHBG (0.36) | SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029535-B2 | Pyrimidine derivatives and their use in perfume compositions | INTERNATIONAL FLAVORS & FRAGANCES INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029535-B2 | Pyrimidine derivatives and their use in perfume compositions | INTERNATIONAL FLAVORS & FRAGANCES INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029535-B2 | Pyrimidine derivatives and their use in perfume compositions | INTERNATIONAL FLAVORS & FRAGANCES INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20150057206-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN PERFUME COMPOSITIONS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057206-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN PERFUME COMPOSITIONS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057206-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN PERFUME COMPOSITIONS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057206-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN PERFUME COMPOSITIONS | DPYD, UMPS, TYMS | CYP19A1 1317/4885AKR1B10 1814/4885AKR1B1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.